The global genitourinary drugs market size is projected to register a high CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increasing prevalence of genitourinary disorders and increasing number of pipeline drugs.
Genitourinary tract agents are the medicines used to diagnose situations of the excretory system and reproductive organs. These medicines are used to prevent preterm labor, urinary modifiers, and medicines for erectile dysfunction in men. The rising incidence of genitourinary disorders and rising number of pipeline drugs are expected to enlarge the scope for the market. Currently, the wide range of generics and counterfeit launched by large pharmaceutical companies and medium-sized drug manufacturers are presumed to affect the market.
The vast pipeline drugs with a high chance of clearing medical trials in the future is anticipated to perform the market at a rapid pace. Meanwhile, Nektar Therapeutics collaborated with Bristol-Myers Squibb to analyze the coupled efficacy and Opdivo in treating five tumor types, including bladder cancer in September 2016. Moreover, continual patent expirations during the forecast period are presumed to hamper the growth of this sector.
Market Trends, Drivers, Restraints, and Opportunities
- Increasing prevalence of genitourinary disorders is expected to be a key driver for the market growth.
- Growing number of pipeline drugs and rapid development of new drugs for the treatment are expected to widen the scope for the market growth in the coming years.
- High probability of clearing medical trials of drugs in the future is expected to serve as a significant growth driver.
- Arrival of a wide range of generics and counterfeit launched by big pharmaceutical companies along with the expansion of small and medium scale drug manufacturers are expected to hamper the market growth.
- Ongoing R&D programs and advancement of technology for the development of drugs are major factors offering massive opportunities for the market expansion in the long run.
Scope of the Report
The report on the global genitourinary drugs market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Genitourinary Drugs Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
Indications (Ovarian Cancer, Prostate Cancer, Bladder Cancer, Renal Cancer, Cervical Cancer, Erectile Dysfunction, Urinary, Incontinence & Overactive Bladder, Sexually Transmitted Diseases, Interstitial Cystitis, Urinary Tract Infections, Hematuria, and Benign Prostatic Hyperplasia) and Products (Hormonal Therapy, Urologicals, Gynecological, Anti-infectives, and Others)
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report
Astellas Pharma US, Inc.; GlaxoSmithKline plc.; Antares Pharma, Inc.; Allergan plc.; Bayer AG; Eli Lilly and Company; Merck KGaA; Bristol-Myers Squibb Company; Abbott Healthcare; Genentech USA, Inc.; Novartis International AG; Teva Pharmaceutical Industries Ltd.; F. Hoffman-La Roche AG; Astrazeneca Pharma India Ltd; Pfizer Inc.; and Advanz Pharma Corp.
Market Segment Insights
Prostate cancer segment is expected to grow at a rapid pace
Based on indications, the global genitourinary drugs market is divided into ovarian cancer, prostate cancer, bladder cancer, renal cancer, cervical cancer, erectile dysfunction, urinary, incontinence & overactive bladder, sexually transmitted diseases, interstitial cystitis, urinary tract infections, hematuria, and benign prostatic hyperplasia. The prostate cancer segment is expected to grow at a rapid pace during the forecast period owing to wide range of available therapeutic of the particular disease type. However, the hematuria segment is anticipated to expand at a robust growth rate during the forecast period due to large investment on R&D by key market players.
Gynecological segment is projected to expand at a considerable CAGR
On the basis of products, the market is divided into hormonal therapy, urologicals, gynecological, anti-infectives, and others. The gynecological segment is projected to expand at a considerable CAGR during the forecast period owing to presence of wider product range for reproductive disorders. Meanwhile, the hormonal therapy segment is attributed to account for a key market share during the projected period due to advancement in technology.
North America is anticipated to constitute a key market share
In terms of regions, the global genitourinary drugs market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to constitute a key market share in the coming years due to high prevalence of huge genitourinary diseases in this region. The market of Asia Pacific, however, is anticipated to exhibit substantial growth during the forecast period owing to continual improvements in healthcare infrastructure and growing awareness among people of these emerging economies in the region.
Segments Covered in the Report
The global genitourinary drugs market has been segmented on the basis of
- Ovarian Cancer
- Prostate Cancer
- Bladder Cancer
- Renal Cancer
- Cervical Cancer
- Erectile Dysfunction
- Incontinence & Overactive Bladder
- Sexually Transmitted Diseases
- Interstitial Cystitis
- Urinary Tract Infections
- Benign Prostatic Hyperplasia
- Hormonal Therapy
- Asia Pacific
- North America
- Latin America
- Middle East & Africa
- Astellas Pharma US, Inc.
- GlaxoSmithKline plc
- Antares Pharma, Inc.
- Allergan plc
- Bayer AG
- Eli Lilly and Company
- Merck KGaA
- Bristol-Myers Squibb Company
- Abbott Healthcare
- Genentech USA, Inc.
- Novartis International AG
- Teva Pharmaceutical Industries Ltd.
- F. Hoffman-La Roche AG
- Astrazeneca Pharma India Ltd
- Pfizer Inc.
- Advanz Pharma Corp.
Key players competing in the global genitourinary drugs market are Astellas Pharma US, Inc.; GlaxoSmithKline plc; Antares Pharma, Inc.; Allergan plc; Bayer AG; Eli Lilly and Company; Merck KGaA; Bristol-Myers Squibb Company; Abbott Healthcare; Genentech USA, Inc.; Novartis International AG; Teva Pharmaceutical Industries Ltd.; F. Hoffman-La Roche AG; Astrazeneca Pharma India Ltd; Pfizer Inc.; and Advanz Pharma Corp. The main market players are continuously engaged in various business development strategies such as mergers and acquisitions, research and developments, investments for innovative products and collaborations. Genentech, Inc. received the US FDA approval for its product, Tecentriq to treat patients suffering from bladder cancer in May 2016.